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Abstract
Background: Deinagkistrodon acutus envenomation is associated with severe hematological and wound complications
but is rarely described.
Case presentation: Herein, we report three cases of victims bitten by D. acutus and indicate that rapid-onset severe
coagulopathy and thrombocytopenia are distinct features of D. acutus snakebite, which are not observed in other
crotaline snakebites (i.e., Trimeresurus stejnegeri and Protobothrops mucrosquamatus) in Taiwan. The toxic effects could
occur as early as 2 to 3 h following D. acutus envenomation and persist if the administration of specific antivenom is
delayed or even not commenced. Based on our findings, 2 to 4 vials of specific antivenom as the first dose should be
administered to victims and repeated at 6 to 8 h intervals if coagulopathy or thrombocytopenia persists. Fresh frozen
plasma or platelet replacement is probably safe as an adjunct therapy for D. acutus bite in the presence of venom-
induced consumptive coagulopathy.
Conclusion: Severe coagulopathy and thrombocytopenia could occur as early as 2 to 3 h after D. acutus envenomation.
The current recommendation for antivenom is 2 to 4 vials as the first dose and repeated every 6– to 8 h if coagulopathy
or thrombocytopenia persists. These cases studied may be helpful to first-line medical personnel in the early diagnosis
and management of D. acutus envenomation among other crotaline snakebites in Taiwan.
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Background
Envenomation caused by snakebite comprises a worldwide
public health problem, especially in Asia [1]. The venoms
of snakes are a fascinating mix that allow the design of
new drugs for use in medicine, as well as being a challenge
for researchers in the development of specific antivenoms
[2–5]. In Taiwan, six major venomous snakes are found,
namely: Trimeresurus stejnegeri, Protobothrops mucrosqua-
matus, Deinagkistrodon acutus and Daboia siamensis in
the family Viperidae, and Naja atra and Bungarus multi-
cinctus in the family Elapidae [6]. D. acutus – also known
as the hundred pacer, five pacer or Chinese moccasin – is
the largest snake (80–155 cm) of the subfamily Crotalinae
on the island [6]. It is additionally distributed throughout
south China, Vietnam and possibly Laos [7]. D. acutus
envenomation is rare; however, it is considered the most
lethal and can result in life- or limb-threatening complica-
tions after envenomation [6, 8]. Although severe coagulop-
athy and thrombocytopenia, defined as an international
normalized ratio (INR) of prothrombin time (PT) > 9 and
platelet count < 50,000/mm3, are considered the hallmarks
of D. acutus envenomation, little is known about the tim-
ing of onset and treatment with specific antivenom [9–13].
In the present study, we summarize the clinical manifesta-
tions and treatment of three cases of D. acutus envenom-
ation admitted to Taichung Veterans General Hospital
(VGH-TC) with the aim of improving the diagnosis and
management of D. acutus envenomation.
Case Presentation
Case 1
A 36-year-old previously healthy man was bitten on his
right hand by a snake during cleaning work around his
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home. He was immediately sent to a local hospital, with
the dead snake identified as D. acutus. However, only
two vials of antivenom for T. stejnegeri and P. mucros-
quamatus were administered, because specific anti-
venom for D. acutus was not available and because the
treating physician believed that cross-neutralization
would occur. He received right upper limb fasciotomy
on day 2 for suspected compartment syndrome. On day
3, he was transferred to VGH-TC due to worsening of
his general condition and bleeding tendency. On arrival,
the patient’s blood pressure (BP) was 109/47 mmHg,
pulse 119/min, respiratory rate 20/min, and body
temperature 38.5 °C.
Physical examination revealed continuous oozing from
the wound and venous catheter insertion site, multiple
hemorrhagic bullae, swelling extending up to the shoulder
and gross hematuria in the urinary bag. Laboratory examin-
ation revealed a hemoglobin level of 5.8 g/dL (reference
range 14–18 g/dL), platelet count 17,000/mm3 (reference
range 150,000–400,000/mm3), fibrinogen 130 mg/dL (refer-
ence range 200–400 mg/dL), D-dimer > 1 μg/mL (reference
range < 0.55 μg/mL), fibrinogen degradation products
(FDPs) > 40 μg/mL (reference range < 10 μg/mL), and
incoagulable blood [PT > 169 s; activated partial thrombo-
plastin time (aPTT) > 224 s] (Table 1).
Three vials of monovalent antivenom for D. acutus and
blood components [600 mL of packed red blood cells,
600 mL of fresh frozen plasma (FFP), and 300 mL of plate-
let concentrate] were immediately administered, resulting
in a good response (Fig. 1). The patient’s blood coagula-
tion normalized at 6 h after administration of the anti-
venom and oozing from the wound stopped. A follow-up
coagulation profile did not reveal recurrent coagulopathy
on days 4, 10 and 13. He had intermittent fever, and ex-
tensive wound necrosis that required repetitive debride-
ment on days 8, 12 and 17 during hospitalization. Deep
tissue cultures obtained during surgery grew Pseudomonas
aeruginosa, Morganella morganii, Staphylococcus aureus
and Enterococcus spp. Although thrombocytopenia per-
sisted throughout days 4 to 10 (22,000–116,000/mm3), it
was amenable to platelet transfusion and medical treat-
ment. The bite wound improved gradually after antibiotic
therapy and debridement. Staged wound closure was per-
formed 3 weeks post-bite, and he was transferred to an-
other hospital for a rehabilitation program 1 month later.
Case 2
A 41-year-old previously healthy woman was bitten on
the left ankle by a snake while she collected herbs in
northwestern Taiwan. She was sent to a local hospital
3 h later, where thrombocytopenia (3000/mm3) and
incoagulable blood (PT > 100 s) were noted. The snake
was identified as D. acutus by the patient through a pic-
ture; however, two vials of antivenom for T. stejnegeri
and P. mucrosquamatus were administered for an un-
known reason. She was then referred to VGH-TC 7.5 h
post-bite.
On arrival, her BP was 172/94 mmHg, pulse 108/min,
respiratory rate 20/min, and body temperature 39.3 °C.
Physical examination revealed many hemorrhagic bullae
scattered along the calf, continuous oozing from the fang
marks, and painful swelling extending to the knee region.
Laboratory examination disclosed thrombocytopenia
(14,000/mm3) and PT of > 169 s and aPTT of > 224 s.
Four vials of monovalent antivenom for D. acutus and
blood components (200 mL of FFP and 300 mL of platelet
concentrate) were administered at 8.5 h post-bite. Her co-
agulation profiles normalized at 15 h post-bite. On day 2,
her platelet count increased to 158,000/mm3. Due to pro-
longed aPTT (43.3–44.6 s), another seven vials of anti-
venom (2 to 3 vials every 6 to 8 h) were sequentially
administered without measurable responses.
Table 1 Initial blood laboratory data of the three patients at
Taichung Veterans General Hospital
Laboratory data (On arrival, day 1) Case 1 Case 2 Case 3




Neutrophil 76.9 84.7 44







Sodium (mEq/L) 136 142 144




Creatinine (0.7–1.4 mg/dL) 0.7 1.4 0.9
Alanine aminotransferase





Total bilirubin (0.2–1.6 mg/dL) 1.3 0.8 –




Creatine kinase (10–160 U/L) 855 745 155




Fibrinogen (200–400 mg/dL) 130 – 149.1
D-dimer (<0.55 μg/mL) >1 – –
Fibrinogen degradation products
(FDPs < 10 μg/mL)
>40 – >40
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The leg wound was complicated with necrotizing
fasciitis that required repetitive debridement on days
21 and 31 and supplemental hyperbaric oxygen ther-
apy. The wound cultures obtained during surgery
revealed S. aureus, Enterococcus spp. and Bacteroides
fragilis. After antibiotic treatment, her wound infec-
tion improved and split-thickness skin grafting was
performed after debridement on day 31. The patient
was discharged on day 47 post-bite with good func-
tional recovery of the leg.
Case 3
A 69-year-old previously healthy woman was bitten on
the left middle finger by a snake while collecting fire-
wood. Painful swelling, tissue ecchymosis, and oozing
from the wound developed a few minutes later. The pa-
tient was sent to VGH-TC 2 h post-bite. The dead snake
brought in by the patient was identified as D. acutus. On
arrival, her BP was 200/120 mmHg, pulse 95/min, re-
spiratory rate 22/min, and body temperature 36.7 °C.
Physical examination revealed swelling of left hand. A
low platelet count (17,000/mm3), PT > 169 s, aPTT >
224 s, fibrinogen level 149.1 mg/dL and FDPs > 40 μg/
mL were noted in laboratory analyses.
Four vials of monovalent antivenom for D. acutus and
1000 mL of FFP were administered. Seven hours post-bite,
both PT and aPTT normalized, and the platelet count in-
creased to 230,000/mm3. Because of recurrent oozing
from the wound, another four vials of antivenom (two at
12 h intervals) were administered without examination of
PT and aPTT levels in the following 24 h. Although the
surgeon recommended partial finger amputation due to
finger necrosis, the patient declined and insisted on being
discharged against medical advice on day 5. No recurrent
coagulopathy was noted prior to discharge; however, the
patient did not return for follow-up.
Discussion
T. stejnegeri and P. mucrosquamatus account for more
than 70% of snakebite cases each year in Taiwan, which
share similar clinical manifestations as well as the same
treatment with bivalent specific antivenom [6, 8]. Sporadic
cases with INR above 1.67 and platelet counts of 36,000/
mm3 were reported in P. mucrosquamatus envenomation,
and none manifested systemic bleeding [11, 14]. In con-
trast, severe coagulopathy and thrombocytopenia are the
main laboratory findings of D. acutus envenomation in
addition to serious wound complications and systemic
bleeding [11–13]. Valenta et al. [15] reported a victim of D.
acutus bite who developed incoagulable blood between 1.5
and 7 h post-bite. Hung et al. [13] reported the case of a
man with persistent thrombocytopenia 44 h after en-
venomation; his platelet level was normal 30 min post-bite.
In our observation, rapid-onset and severe coagulopathy
and thrombocytopenia developed as early as 2 to 3 h post-
bite may persist if correct antivenom is not administered.
D. acutus venom is composed of several hemotoxins, in-
cluding the thrombin-like enzymes (TLEs), anticoagulant
toxins, platelet aggregation inhibitors, hemorrhagins, and
enzymes that facilitate venom spreading [16–19]. The
anticoagulation effect of TLEs occurs rapidly, and circulat-
ing fibrinogen levels start to fall within 30 min, reaching
9% of the normal value within 2 h [16]. Anticoagulant
toxins inactivate prothrombin, tissue factor and coagula-
tion factors V and IX/X, resulting in a transient but marked
Fig. 1 a Trend of PT in three patients. b Trend of aPTT in three patients.
c Trend of platelet level in three patients. F: fresh frozen plasma
transfusion. P: platelet concentrate transfusion
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prolongation of blood coagulation within 5 min after in-
jection [16, 20, 21]. The platelet inhibitors, mainly adeno-
sine diphosphatase, inhibit platelet aggregation in the
presence of adenosine diphosphate or collagen [17]. The
hemorrhagins (e.g., snake venom metalloproteinases)
cause extensive vascular damage and increase vascular
permeability [22]. These effects may explain the remark-
able bleeding tendency and wound complications in D.
acutus envenomation.
The Taiwan government produces four types of anti-
venom against the six major venomous snakebites [8]. Con-
cerning the monovalent antivenom for D. acutus, each vial
roughly neutralizes 52 mg of venom. The Taiwan Poison
Control Center thus recommends that 2 to 4 vials of anti-
venom be administered in a envenomed patient because
the mean amount of D. acutus venom injected is 105.1 mg
[8]. However, this recommendation was not validated and
there is no standard dosing regimen available in Taiwan.
According to our findings, the current recommendation is
2 to 4 vials of antivenom to be administered as the first
dose and repeated at 6 to 8 h intervals if coagulopathy or
thrombocytopenia persists (e.g., INR > 3, aPTT > 50s, and
platelet level < 20,000/mm3) [23, 24]. Although cross-
neutralization occurs between bivalent antivenom for T.
stejnegeri and P. mucrosquamatus and monovalent anti-
venom for D. acutus, substitution should be avoided as the
bivalent antivenom has only a weak cross-reactivity with
the D. acutus venom [13].
All of our cases had a rapid improvement in coagulop-
athy after receiving specific antivenom. In case 2, s
slightly prolonged aPTT persisted for 4 days without
clinical thrombosis or bleeding tendency. Although a
workup for prolonged aPTT was not performed in the
case, it was probably unrelated to the venom because no
apparent response was observed after repetitive anti-
venom administration [25]. In case 1, thrombocytopenia
did not show improvement after antivenom therapy,
which was probably attributable to uncontrolled infec-
tion. Nevertheless, Valenta et al. [15] reported a single
case of D. acutus envenomation who manifested severe
coagulopathy in the absence of thrombocytopenia.
Therefore, the exact mechanism of thrombocytopenia in
D. acutus snakebite remains unclear.
Evidence suggests that, when compared with anti-
venom alone, early FFP replacement therapy shortens
coagulopathy in patients suffering from hemotoxic snake
envenomation and, theoretically, lower the risk of major
bleeding [26]. The bleeding risk may be pronounced in
cases of severe thrombocytopenia [10]. However, in
cases of venom-induced thrombotic microangiopathy,
platelet transfusion may be problematic [27]. In our
study, no elevation of blood bilirubin or lactate dehydro-
genase was found, and the first two cases had received
platelet concentrate transfusions, resulting in good
responses. It appears to be safe to use the blood compo-
nent therapy during D. acutus envenomation. In case 3,
the platelet count spontaneously normalized after 24 h
with FFP and specific antivenom administration alone.
This effect may have occurred because of the relatively
modest injury in this case. However, the patient received
a higher dosage (eight vials) of antivenom, which was
sufficient to counteract the venom effects on platelets.
Conclusion
Severe coagulopathy and thrombocytopenia could occur
as early as 2 to 3 h after D. acutus envenomation. The
current recommendation for antivenom therapy is 2 to 4
vials as the first dose and repeat it every 6 to 8 h if coag-
ulopathy or thrombocytopenia persists. Our observation
may be helpful to first-line medical personnel in the
timely diagnosis and management of D. acutus bites.
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